GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:13 2024-07-17 EDT			5-day change	1st Jan Change
1,528 ^GBX	+1.83%		+1.56%	+5.40%

07-17	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT
07-17	EU court criticizes Commission over handling of COVID vaccine contracts	RE

GSK : Jefferies sticks Neutral

January 05, 2023 at 03:53 am

Analyst Peter Welford from Jefferies research gives the stock a Neutral rating. The target price is being increased from GBX 1475 to GBX 1575.

Latest news about GSK plc

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	07-17	MT
EU court criticizes Commission over handling of COVID vaccine contracts	07-17	RE
Emma Walmsley, CEO of GSK: Antimicrobial resistance, a public health issue	07-16	MT
National Advisory Committee On Immunization Recommends RSV Vaccines, Including Arexvy, For Older Adult Populations	07-16	RE
GSK: RSV VACCINATION RECOMMENDED FOR CONSIDERATION BY ADULTS AGE…	07-16	RE
EQT Unit Invests in Biotechnology Company Asceneuron	07-16	MT
Second malaria vaccine launched in Ivory Coast in new milestone	07-15	RE
GSK: ViiH Healthcare to present its advances in HIV	07-15	CF
GSK to Move Global Headquarters in London	07-14	MT
GSK moves to new global headquarters in return to central London	07-14	AN
European Equities Close Higher Thursday; UK GDP Grows More Than Expected	07-11	MT
GSK: first shipments of flu vaccines to the USA	07-11	CF
GSK Begins Shipping Flu Vaccines Flulaval, Fluarix	07-11	MT
GSK: EXPECTS TO DISTRIBUTE OVER 36 MLN DOSES OF ITS TRIVALENT IN…	07-11	RE
GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season	07-11	CI
GSK : Deutsche Bank reiterates its Buy rating	07-10	ZD
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births	07-08	RE
UBS Downgrades GSK to Neutral From Buy	07-08	MT
That's not so bad, is it?	07-08
ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment	07-08	MT
UBS Downgrades GSK to Neutral from Buy, Cuts PT	07-08	MT
ITeos Therapeutics, Inc. Announces First Patient Dosed in Galaxies Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK	07-08	CI
UBS cuts GSK; RBC raises Melrose Industries	07-08	AN
GSK : UBS downgrades its recommendation	07-08	CF
Carlsberg to buy Britvic in GBP3.3 billion deal	07-08	AN

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Emma Walmsley, CEO of GSK: Antimicrobial resistance, a public health issue

July 16, 2024 at 08:19 am

GSK PLC : Frightened markets create an entry opportunity in GSK

June 04, 2024 at 08:38 am

GSK plc : Back on track

May 03, 2024 at 05:17 am

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.28 GBP

Average target price

19.88 GBP

Spread / Average Target

+30.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+5.40%	79.3B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

GSK : Jefferies sticks Neutral

Latest news about GSK plc

Chart GSK plc

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for GSK plc

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals